


Name/Surname		Pär STATTIN, Professor MD, PhD
Affiliation	Adjunct Professor, Consultant, Department of Surgical Sciences, Uppsala University, Sweden & Researcher, Department of Surgical and Perioperative Sciences, Department of Urology and Andrology, Umeå University, Sweden	
IARC Host Group	Section of Cancer Surveillance, IARC, Dr Freddie Bray	
Speciality	Urology. Dr Stattin´s research focus is on prostate cancer investigating predictive biomarkers, etiological hormonal factors, clinical outcome, and pattern of care.	
Academic Degrees	1997: Ph.D, Prognostic factors in prostate cancer. Urology and Pathology, Umeå University, Sweden 1991: Specialist in Urological Surgery, Västerås Central Hospital, Sweden 1986: Authorized physician, Västerås Central Hospital, Sweden 1984: Medical doctor (MD), Uppsala University Hospital, Sweden	
Selected Publications	<ul style="list-style-type: none"> <li>• Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. J Natl Cancer Inst. 2016 Jul 10;108(10).</li> <li>• Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, Lambe M. Work Disability After Robot-assisted or Open Radical Prostatectomy: A Nationwide, Population-based Study. Eur Urol. 2016 Jan 15.</li> <li>• Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base-a refined prostate cancer trajectory. Int J Epidemiol. 2015 Dec 11.</li> <li>• K Tomic, F Sandin, A Wigertz, D Robinson, Mats Lambe, P Stattin. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer Nov 2014.</li> <li>• Stattin P, Sandin F, Sandback T, Damber JE, Franck Lissbrant I, Robinson D, et al. Dashboard report on performance on select quality indicators to cancer care providers. Scand J Urol. 2015</li> <li>• S Loeb, Y Folkvaljon, D Robinson, T Schlomm, H Garmo, P Stattin. Phosphodiesterase type 5 inhibitors (PDE5i) use and recurrence after prostate cancer treatment. Eur Urol, 2015</li> <li>• Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P. Risk of malignant melanoma in men with prostate cancer. Nationwide,</li> </ul>	

population-based cohort study. *Int J Cancer*. 2015

- Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. *JAMA*. 2015
- Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. *Eur Urol*. 2015
- O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. *J Clin Oncol* . 2015
- P Stattin, A Vickers, D. Sjoberg, R Johansson, T Granfors, , M Johansson, K Pettersson, P Scardino, G Hallmans, H Lilja. Improving the specificity of screening for lethal prostate cancer using PSA and a panel of kallikrein markers: a nested case-control study. *Eur Urol* 2015
- P Stattin, S Carlsson, B Holmström, A Vickers, J Hugosson, H Lilja, H Jonsson. Prostate Cancer Mortality in Areas with High and Low Prostate Cancer Incidence. *JNCI*. 2014
- Robinson D, Garmo H, Bill-Axelsson A, Mucci L, Holmberg L, Stattin P. Use of 5 $\alpha$ -reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. *BMJ* 2013
- Friðriksson JO, Holmberg E, Adolfsson J, Lambe M, Bill-Axelsson A, Stefan C, Hugosson J, Stattin P. Readmission after Radical Prostatectomy in a Nationwide, Population-based Study. *J Urol* 2014 Feb.
- Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B. Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case-Control Study within PCBaSe Sweden. *Cancer Epidemiol Biomarkers Prev*. 2013
- Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TM, Dickman PW. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. *Cancer Causes & Control* 2013 Mar
- Rider, Sandin, André, Wiklund, Hugosson, Stattin. Long-term Outcomes Among Non-Curatively Treated Men According to Prostate Cancer Risk Category in a Nation-wide, Population-Based Study. *Eur Urol* 2012 Aug.
- Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelsson A, Lambe M, Stattin P, Adolfsson J. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. *J Clin Oncol*. 2010
- Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J, National Prostate Cancer Register (NPCR). Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden

	<p>follow-up study. J Natl Cancer Inst. 2010;102(13):950-8.</p>
<p>Programme at IARC</p>	<p>Interpretation of current trends in world-wide prostate cancer incidence and mortality by use of comprehensive data in a nation-wide, population-based clinical cancer register</p>
<p>Short background</p>	<p>Professor Stattin is Adjunct Professor and Consultant at the Department of Surgical Sciences, Uppsala University, Sweden and keeps his affiliation as researcher at the Department of Surgical and Perioperative Sciences, Department of Urology and Andrology, Umeå University, Sweden (20 %), where he used to be Professor from 2009 to 2016.</p> <p>Professor Stattin received his Medical Diploma from the Uppsala University Hospital in 1984, obtained his Specialty in Urological Surgery at the Västerås Central Hospital in 1991 and was awarded his PhD in 1997 (“Prognostic factors in prostate cancer”).</p> <p>Foreign research stays include Postdoc at the International Agency for Research on Cancer from 2002-2003 (as) and Visiting scientist at the Department of Surgery, Urology Service, at the Memorial Sloan-Kettering Cancer Center in New York, NY, USA from 2011-2013.</p> <p>Professor Stattin is the Coordinator of studies on prostate cancer in Northern Sweden Health and Disease cohort (NSHDC), Principle investigator of the Prostate Cancer database Sweden (PCBaSe) since 2007 and is Chairman of the National Prostate Cancer Register of Sweden since 2006.</p> <p>Professor Stattin has published more than 300 peer reviewed articles.</p>